All posts by imreal

The Added Value of Biostatistics-Driven Randomization and Trial Supply Management System, Upcoming Webinar Hosted by Xtalks


As clinical trials become increasingly complex, biostatisticians become even more essential, providing the needed insight to understand protocol-specific randomization nuances and make optimal randomization decisions to improve trial outcomes.

Randomization and trial supply management (RTSM) and electronic data capture (EDC) technologies and systems are essential to managing clinical trials. As clinical trials become increasingly complex, biostatisticians become even more essential, providing the needed insight to understand protocol-specific randomization nuances and make optimal randomization decisions to improve trial outcomes. In this case study-focused webinar, the featured speakers will highlight how biostatistics is crucial at multiple stages of clinical trials such as study design, randomization implementation, rerandomization needs, randomization and drug supply checks, unblinding and final analysis.

Register to learn about the added value of biostatistics in randomization and trial supply management system solutions for clinical trials.

Join Paul Vanbosterhaut, Sr. RTSM System Specialist, IDDI; and Anthony Warren, Director, Technical Product Management, Clario, for the live webinar on Wednesday, January 25, 2023, at 9am EST (3pm CET/EU-Central).

For more information, or to register for this event, visit The Added Value of Biostatistics-Driven Randomization and Trial Supply Management System.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com

For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Contact:

Vera Kovacevic

Tel: +1 (416) 977-6555 x371

Email: vkovacevic@xtalks.com

Share article on social media or email:

NYC Based IV DRIPS, Known for IV Therapy and Infusions, Announces their New Semaglutide Weight Loss Program


News Image

“We are thrilled to offer this opportunity for clients to benefit from our successful weight loss solution, and as an introductory special, we are offering 10% off for the initial program,” says Bracha L. Banayan, NP.

IV DRIPS Customized IV Hydration & Wellness understands that true health starts with a body that is in balance. The team is excited to offer clients a revolutionary treatment for obesity and chronic overweight conditions, Semaglutide, (prescribed under brand names Wegovy and Ozempic). It is the first FDA-approved weight-loss drug to come to market since 2014. The IV DRIPS “Weight Loss Program” is designed to empower and allow clients to take greater control of their life by pairing effective weight loss injections with minimal restrictions and subtle changes to diet and exercise. Administered by self-injection under the skin once each week, Semaglutide works by mimicking a hormone–termed glucagon-like peptide-1 (GLP-1) which targets the body’s appetite-controlling receptors, effectively triggering the brain’s “I’m full” message after eating. Semaglutide also works to slow down “gastric emptying,” which is the process by which stomach contents are transferred into the first portion of the small intestine in the digestive process. IV DRIPS’ medical team will meet with clients via video call (consultation) to discuss the program and go over specific lifestyle details, goals and review both bloodwork and medical history to confirm eligibility for the program. Once approved, the Semaglutide B12 prescription will be filled along with a scheduled one-on-one appointment to teach and support patients in successfully performing self-injections (initial program). Each month, patients will consult with the IVDRIPS’ medical team to continue the weight loss journey in the easiest, yet most effective way.

“We are thrilled to offer this opportunity for clients to benefit from our successful weight loss solution, and as an introductory special, we are offering 10% off for the initial program,” says Bracha L. Banayan, NP.

More About IV Drips Customized IV Hydration & Wellness:

IV DRIPS Customized IV Hydration & Wellness was founded by Bracha L. Banayan, NP. The team of registered nurses and practitioners are specialized in IV infusions with multiple service locations in the U.S. IV DRIPS has carefully selected the most critical nutrients and vitamins for health and formulated drips with the perfect blend that complements and supports each other. IV DRIPS’ mobile intravenous therapy provides safe, in-home IV infusions with essential fluids, electrolytes, vitamins and antioxidants to quickly remedy a variety of conditions, as well as NAD+, a revolutionary anti-aging and regenerative treatment. IV DRIPS also offers clients the opportunity to sign up for Gold and Platinum VIP memberships to receive personalized medical concierge services.

To find out more about IV Drips Customized IV Hydration & Wellness or to schedule concierge IV drip therapy across the country, please visit http://www.ivdrips.com or call 212-220-3957. For specific information on the new weight loss program, please visit http://www.ivdrips.com/weight-loss-program.

Share article on social media or email:

NGD and CEO Paul Rhodes Announce Publication in mSphere


Next Gen Diagnostics and CEO Paul Rhodes Announce the Publication in mSphere of a Report Validating the Accuracy of NGD’s Automated Bioinformatic System for the Detection of Transmission of Infection

Next Gen Diagnostics announces the publication in mSphere of a study validating the accuracy of its fully automated bioinformatics platform for the detection of transmission of infection. Titled “Large-scale evaluation of a rapid fully automated analysis platform to detect and refute outbreaks based on MRSA genome comparisons” and led by University of Cambridge Professor and NGD Scientific Advisory Board member Sharon Peacock, the study compared the detection of transmission clusters by the gold standard manual bioinformatics pipeline developed by the Peacock group for previous seminal publications on hospital transmission with the automated NGD system. Analyzing 3,311 case pairs, the paper reports that both the manual bioinformatics system and the NGD automated pipeline identified the same 66 transmission clusters. The authors concluded “…that [NGD’s] automated transmission detection tool worked at least as well as a researcher-led manual analysis and indicates how such tools could support the rapid use of MRSA genomic epidemiology in infection control practice.”

“We have seen our system enable the power of prospective sequencing to detect transmission and guide intervention to stop outbreaks,” noted Paul A. Rhodes, Ph.D., Next Gen Diagnostics CEO. “Now with this new publication from Professor Peacock’s group the accuracy of the NGD automated bioinformatics system’s computation of SNP-level relatedness between infections has been quantitatively validated. By combining high quality automated bioinformatics with our low-cost automated microfluidic library preparation system we will make prospective sequencing practical as the new paradigm for the detection of transmission and prevention of outbreak in hospitals, where transmission of drug resistant infection is such an appalling problem.”

NGD has combined world-class fully automated bioinformatics, validated in published clinical studies, with a revolutionary microfluidic sample preparation system to offer a low cost, overnight complete pathogen WGS service. NGD’s exclusive microfluidic sample preparation system reduces reagent volumes >10-fold, is highly compact and automated, and enables 48 bacterial samples to be simultaneously processed in an instrument the size of a desktop computer using a disposable the size of a single plate.

“We knew that a rigorous quantification of the accuracy of the NGD automated bioinformatics system was a key prerequisite for its consideration in clinical use,” said Professor Peacock, NGD Scientific Advisory Board member. “With this study, coupled with our earlier work1 reporting the successful clinical application of the NGD system to detect outbreaks, the time has come to consider prospective sequencing combined with automated bioinformatics as a foundation of hospital infection control practice.”

About Next Gen Diagnostics

NGD, founded by Paul Rhodes, the former CEO of Specific Diagnostics, along with Sanger Institute group leaders, has built and validated world-leading automation of pathogen bioinformatics enabling high throughput low cost clinical use of WGS. In addition, NGD holds the exclusive rights to a transformative microfluidic sample preparation system for all clinical and commercial applications of pathogen WGS. NGD offers high volume turn-key sequencing services to enable detection of transmission in hospitals, and is working with leading collaborators in the US, Europe and Israel to be the first to bring WGS-based regulated diagnostics to patient care. NGD is based in the US, with an office in Cambridge, UK and a subsidiary in Israel. For press inquiries, please contact: press@nextgen-dx.com

Share article on social media or email:

BreakThrough Physical Therapy Opens New Clinic in East Raleigh


News Image

“This clinic is a great opportunity for us to meet the needs of our patients and offer excellent customer service/care to the East Raleigh community. I look forward to helping the community work to achieve their optimal level of function.” – Sean Duggan, East Raleigh Clinic Director

BreakThrough Physical Therapy (BTPT) is pleased to announce their newest clinic has opened today in Raleigh, NC. Located at 7540 Ramble Way, Suite 101, the clinic is BreakThrough’s 23rd location.

Sean Duggan, PT, DPT, MTC, OCS, will serve as the East Raleigh Clinic Director and primary treating physical therapist.

BTPT specializes in providing exceptional physical therapy through a combination of evidence-based practice, care excellence, and clinical excellence. Services offered from the East Raleigh clinic will include orthopedics and sports injuries, chronic pain/virtual reality, dry needling, headaches, manual physical therapy, neck pain, post-COVID therapy, spine care, TMJ, vertigo, workplace injuries and work conditioning.

The clinic will also include BreakThrough Golf, MVA-related injuries, soft tissue mobilization, and Stand Up 2 Stenosis.

“I am excited to be opening this new location in East Raleigh, and to be a part of the BTPT team,” says Duggan. “This clinic is a great opportunity for us to meet the needs of our patients and offer excellent customer service/care to the East Raleigh community. I look forward to helping the community work to achieve their optimal level of function.”

For more information about the new East Raleigh clinic and a full list of BTPT’s services and offerings, please visit https://breakthrough-pt.com/. To book an appointment with Sean, please call 984-238-2140.

###

About BreakThrough Physical Therapy

BreakThrough Physical Therapy (BTPT) is a North and South Carolina-based, private physical therapy practice group. As a proud member of the Confluent Health family, BTPT positively impacts patients’ lives by delivering the best care and results through proven research, innovative treatments and technologies, and an approach that treats patients like family. For more information, visit breakthroughptclinics.com, or find them on Facebook at @ptbreakthrough.

Share article on social media or email:

Daytryp Health Announces Opening of Flagship Location in Phoenix, AZ


Daytryp Health

Daytryp Health

Daytryp Health, an up-and-coming psychedelic wellness center, announced today the opening of their first location in Phoenix, AZ. It is one of many locations that Daytryp is planning to open in 2023 and beyond. Located in the Arcadia neighborhood, the Phoenix location is the first Daytryp Health center to open this year, and will be followed by locations in Mesa, AZ and Bend, OR.

Daytryp Health centers provide medically supervised ketamine therapy programs combined with psychotherapy in a tranquil, elegant atmosphere. Ketamine is a legal psychedelic compound that has been proven to help those suffering from treatment-resistant depression, anxiety, post traumatic stress disorder (PTSD), chronic pain, migraines, eating disorders, suicidal ideation, and substance and alcohol use disorders. Ketamine induces neuroplasticity, which is the brain’s ability to change – to rewire, relearn and strengthen important connections. Neuroplasticity occurs after every ketamine treatment and can last for many days, providing the opportunity to quite literally “change people’s minds,” as well as their lives.

With the opening of the Phoenix office, Daytryp intends to establish itself as a pillar in the community, providing education on the efficacy and safety of psychedelic therapies on physical, emotional, and mental health. Unlike the majority of existing ketamine clinics, Daytryp applies a holistic approach to wellness with an emphasis on the integration process. The integration process refers to a number of ways in which Daytryp practitioners and “trip sitters” assist clients in processing and incorporating the insights gained from their ketamine treatment. Daytryp will also be participating in clinical trials of additional psychedelic treatments including psilocybin therapy and MDMA therapy.

Chris Cohn, founder and CEO of Daytryp Health stated, “We are very excited to announce Daytryp Health to our community and expand our reach in offering a groundbreaking, proven, and impactful mental health treatment via Ketamine Assisted Psychotherapy. We will emphasize the integration aspect of these therapies, therefore focusing on sustained relief from mental and spiritual health ailments. Our extensive research and clinical experience will provide those suffering from mental, physical, and spiritual ailments with novel and effective treatment pathways. Additionally, Daytryp will provide a vital role in educating providers and consumers about the therapeutic potential of safely utilizing psychedelic compounds in response to the ongoing mental health epidemic.”

Chris Cohn spent the prior 15 years as Founder and CEO of a large drug and alcohol rehab program in Scottsdale, AZ. “After exiting the inpatient drug and alcohol rehab space after 15 years, I cosmically stumbled upon the world of psychedelic medicines for my own mental and spiritual healing. I knew in my heart this was the direction I wanted to go, particularly after all the clinical trials proved these psychedelic medicines to be so effective in healing many mental health ailments including substance abuse addiction, which I’m still very passionate about,” said Cohn.

About Daytryp Health

Envisioned by leading mental health and psychedelic healthcare professionals, Daytryp Health is a privately owned family of psychedelic wellness centers in Arizona and Oregon, providing personalized treatment to help individuals and their loved ones break free from the cycle of chronic mental health and pain conditions.

For more information, please visit https://www.daytryp.com or call 1-833-DAYTRYP

Share article on social media or email:

ProPharma Group Launches Revolutionary New Operating Model To Deliver Life-Saving Drugs, Medical Devices And Diagnostics To Market Faster


ProPharma Group – the end-to-end, global provider of regulatory, clinical and compliance services for the pharmaceutical, biotechnology and medical device industries – today launched the Research Consulting Organization (RCO) model, a new type of research consulting and clinical service for biotech, pharma and device innovators to deliver bespoke solutions that bring life-saving drugs to market sooner and more cost effectively.

Announced at the opening of this year’s J.P. Morgan Healthcare Conference, the new model will provide innovators with unmatched access to the world’s leading strategists to de-risk their most critical programs and provide sponsors and physicians with the greatest probability of success. By drawing on its expertise across areas including regulatory strategy, clinical development, quality and compliance, pharmacovigilance and medical information, the model also harnesses an increased scale of operations and data-driven insights to drive greater R&D productivity for clients, cutting delays and budget overruns.

ProPharma is introducing itself to a global audience for the first time as the world’s largest Research Consulting Organization, underpinned by a $50m investment. The new strategy and operating model are further supported by the launch of a global re-brand, including a modern look and feel for the organization and overarching ProPharma brand. In addition to new branding, existing and prospective clients will enjoy an enhanced digital experience across engagement channels including the website (http://www.propharmagroup.com), social media and client-facing communications.

According to a new White Paper released today, ProPharma is also taking a bold leadership position in a dynamic industry and is confident the life sciences industry at large will benefit from its groundbreaking RCO model. Fit-for-purpose and built-for-the-future, the RCO will benefit clients of all sizes, including emerging clients who may have received less attention in the past; growing clients who require partnership and expertise to achieve momentum and scale; and established clients who require experienced global capabilities coupled with scaled operational support.

The White Paper references major consolidation and huge growth among CROs in recent years. This trend, caused by organizations seeking to secure the biggest returns for shareholders, has left smaller and medium players contending with lesser resources to recruit patients to trial, drastic delays to the approval of medicines and treatments and costly budget overruns.

The White Paper further outlines that smaller programs, for example those developing molecules for rare and orphan diseases, innovative new devices or cell therapies, need bespoke solutions that are readily available and more effectively delivered through the new RCO approach.

Michael Stomberg, CEO of ProPharma Group, said: “The Research Consulting Organization (RCO) model is designed to lead to optimal results and provide a real alternative for sponsors who don’t fit the mold. While we’re unveiling this new model today, the reality is that we’ve been planning this for some time, in light of feedback from our customers.

“The RCO is a fit-for-purpose, built-for-the-future solution that gives the resources our customers need at every point in their development continuum, no matter their size. This innovative approach will act as the umbrella over distinct service offerings, allowing us to provide deep scientific and technical expertise – including access to some of the world’s leading experts – to help sponsors get life-saving drugs and treatment to market faster and more cost-effectively.

“As part of the new operating model and our global re-brand, ProPharma’s purpose, mission and vision are evolving to ultimately further help improve the health and safety for patients around the world.”

###

Media Contact:

Iyana Jones-Reese

Clarity for ProPharma

propharmagroup@clarity.global

916-217-5223

About ProPharma

For the past 20 years, ProPharma has improved the health and wellness of patients by providing advice and expertise that empowers biotech, med device, and pharmaceutical organizations of all sizes to confidently advance scientific breakthroughs and introduce new therapies. As the world’s largest RCO (Research Consulting Organization), ProPharma partners with its clients through an advise-build-operate model across the complete product lifecycle. With deep domain expertise in regulatory sciences, clinical research solutions, quality and compliance, pharmacovigilance, medical information, and R&D technology, ProPharma offers an end-to-end suite of fully customizable consulting solutions that de-risk and accelerate our partners’ most high-profile drug and device programs.

Share article on social media or email:

Ideal Option Opens Second Addiction Clinic in Albuquerque


Ideal Option, a national leader in evidence-based outpatient treatment for addiction to opioids, methamphetamine, alcohol and polysubstance, is now welcoming patients at its newest location at 8400 Osuna Rd NE in Albuquerque. Patients will receive personalized, evidence-based treatment with buprenorphine and other FDA-approved medications from an onsite addiction medicine specialist.

Fentanyl, a dangerous and highly addictive synthetic opioid, is widely available in New Mexico. According to the CDC National Center for Health Statistics, there were 595 drug overdose deaths due to synthetic opioids reported in New Mexico during the 12-month period ending in December 2021, an 89% increase from the 315 deaths reported during the same period the year before.

“What we are hearing from so many folks is…people don’t know that fentanyl is out there and…one pill can kill,” said Adriann Barboa, county commission chair with Bernalillo County.

Ideal Option’s 2021 Annual Patient Outcomes Report for New Mexico shows fentanyl positive rates at enrollment were up by 104% displacing heroin positive rates which were down by 44% compared to 2020. The data also support the effectiveness of treatment. Among patients who remained in treatment with Ideal Option during 2021, urine drug testing shows:

  • 96% less fentanyl use
  • 92% less total opioid use
  • 95% less heroin use
  • 88% less methamphetamine use


The new clinic in Albuquerque comes at a time of desperate need for expanded access to evidence-based treatment from experienced providers. Ideal Option has been specializing in addiction medicine using buprenorphine-based medications such as Suboxone® for 10 years and currently operates 84 clinics across 11 states.

“Because of our scale, we’re able to start new patients within 1-3 days, not several weeks like many other providers who are overwhelmed by the demand. Opening a second clinic in Albuquerque means we can help so many more people start and remain in life-saving treatment,” said Athena Huckaby, community outreach coordinator for Ideal Option in New Mexico.

The new Ideal Option clinic in Albuquerque is open Monday – Thursday, 7:30 a.m. – 6 p.m. and is located at 8400 Osuna Rd NE, Ste. 2D, Albuquerque, NM 87111.

Most forms of insurance are accepted, including Medicare and Medicaid, and patients can typically get started on treatment for fentanyl, heroin, alcohol or other substances within 1-3 business days.

Patients can make an appointment by calling 1.877.522.1275 or visiting http://www.idealoption.com.

About Ideal Option

Headquartered in Kennewick, Washington, Ideal Option was founded in 2012 and has since helped more than 60,000 patients through a network of 84 office-based medication-assisted treatment (MAT) clinics across 11 states. With a mission to serve under-served communities, Ideal Option accepts all forms of insurance including Medicaid and Medicare. Financial assistance and payment plans are also available.

Ideal Option’s team of medical providers carry certifications in Addiction and Emergency Medicine, Internal, and Family Medicine, among other specialties. The company also employs social workers, caseworkers, counselors, and mental health practitioners. This holistic approach helps drive positive outcomes, including family stability, stable housing, improved overall health, and reduced rates of recidivism.

In all the communities it serves, Ideal Option collaborates with existing stakeholders and providers to improve the continuum of care. This approach includes partnerships with emergency rooms and county jail systems, where individuals with substance use disorder often appear, as well as collaborating with numerous support agencies and municipal programs addressing social needs such as housing, mental health, and nutrition support.

Share article on social media or email:

Cancer Nutrition Consortium Releases Cookbook to Provide Cancer Patients with Best Nutrition Possible


 patients health cancer treatment nourishing meals protein shakes

The Cancer Nutrition Consortium works to promote and better understand the importance of food and nutrition to positive medical outcomes of cancer treatment and recovery.

According to a 2015 study, getting proper nutrition is one of the biggest challenges for people undergoing cancer treatment.

Food is one of the basic necessities of life.

But for people fighting cancer, food itself can present a struggle as treatments often affect taste, smells, appetite, nausea and digestion. According to a 2015 study, “The Impact of Cancer Treatment on the Diets & Food Preferences of Patients Receiving Outpatient Treatment”, one of the biggest challenges for people undergoing cancer treatment is getting proper nutrition.

“Cooking Through Treatment”, available now, (all purchases are charitable donations) contains 43 convenient, nutritious recipes tailored to meet the various needs of people during cancer treatment and recovery.

Cooking Through Treatment is unique in that many of the recipes were developed by professional chefs, in conjunction with oncology dietitians at the nation’s leading cancer treatment institutions, including the Dana Farber/Brigham and Women’s Cancer Center, the Mayo Clinic Cancer Center, Ohio State University Wexner Medical Center, New York University Langone’s Laura and Isaac Perlmutter Cancer Center, and The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Based on the results of the groundbreaking unprecedented multicenter clinical research study conducted by the Cancer Nutrition Center (CNC), each recipe included in Cooking Through Treatment was designed to address issues that cancer patients typically confront, which often interfere with getting enough good nutrition, including difficulty swallowing as well as the need for mild flavors. Using a system of nutrition indicators, each recipe is coded for specific nutritional needs, including heart health, high-protein, and energy boosting.

Cooking Through Treatment is produced and published by the Cancer Nutrition Consortium (CNC), a non-profit that works to promote and better understand the importance of nutrition for positive medical outcomes for patients during cancer treatment and recovery.

“The whole key behind the CNC is a scientific approach to maintaining good nutrition at any stage of the diagnosis and treatment of cancer,” said Dr. Bruce Moskowitz, a primary care physician in West Palm Beach and founder of the CNC.

Faced with questions about food and nutrition from patients fighting cancer, Dr. Moskowitz discovered a paucity of research and science-based information. The CNC was created to develop and share that knowledge. In addition to working with physicians and nutrition experts at leading cancer institutions, the CNC also has underwritten 6 scientific research studies of food and nutrition in people undergoing cancer treatment.

“Whether you’re just diagnosed, undergoing treatment, or are a survivor, having knowledge-based information is extremely important,” Moskowitz said.

——–

The Cancer Nutrition Consortium, Inc. is approved as a tax-exempt, not-for-profit 501(c)(3) corporation organized in the State of Florida.

Learn more and find the cookbook at http://www.CancerNutrition.org

Visit the CNC on Twitter, LinkedIn and Facebook.

Share article on social media or email:



New Book Suggests Modern Christian Values May Not Align with Biblical Truth


News Image

I hope readers can discover and support God’s truth in a world of conflicting morals and values,” Beach said. “Many Christians fall into the trap of believing what the world and society teaches, even when those values differ from the values of God.

Those seeking truth and clarity in a world where values are changing rapidly may find answers in new book that seeks to uncover God’s truth.

In “Worldview of the Christian Faith,” by Joseph Charles Beach, readers are provided answers to some of the most complex questions surrounding the Christian faith. Beach explores the relevance of the Bible in today’s modern world and provides biblical context for many other popular questions of the faith.

“I hope readers can discover and support God’s truth in a world of conflicting morals and values,” Beach said. “Many Christians fall into the trap of believing what the world and society teaches, even when those values differ from the values of God.”

During 2020, Beach noticed society’s values were changing and began to question his own beliefs. After spending time researching the truth in the Bible and answering many of his own questions, Beach knew he needed to share his findings. He believed society seemed to be diverging from the biblical truth in God’s word.

“Christianity has a lot to offer,” said Beach. “I hope all people can come to learn the truth of God and accept the grace and love that God has to offer to all His children.”

“Worldview of the Christian Faith”

By Joseph Charles Beach

ISBN: 9781664277472 (softcover); 9781664277489 (hardcover); 9781664277496 (electronic)

Available at WestBow Press, Amazon and Barnes & Noble

About the author

A lifelong resident of the Dallas/Ft. Worth metroplex, Joseph Beach currently resides in Euless, Texas, with his wife of 36 years, Michele. He is a member of Gateway Church in Southlake, Texas. He graduated from the University of Texas, Arlington, with a B.A. in Business Administration and has worked in the stock brokerage business and, for the last 25 years, in the computer software industry. Joseph is a devote believer and follower of Jesus Christ and believes God and the Bible point to ultimate truth and reality. To learn more, please visit https://www.westbowpress.com/en/bookstore/bookdetails/842908-worldview-of-the-christian-faith.

Share article on social media or email: